Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Comprehensive Review About the Utilization of Immune Checkpoint Inhibitors and Combination Therapy in Hepatocellular Carcinoma: An Updated Review Publisher



Sharafi F1 ; Hasani SA2 ; Alesaeidi S3 ; Kahrizi MS4 ; Adili A5, 6 ; Ghoreishizadeh S7 ; Shomali N7 ; Tamjidifar R8, 10 ; Aslaminabad R8 ; Akbari M7, 9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Research Center, Department of General Surgery, Shahid Beheshti University of Medical Science, Tehran, Iran
  3. 3. Department of Internal Medicine and Rheumatology, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Alborz University of Medical Sciences, Karaj, Iran
  5. 5. Senior Adult Oncology Department, Moffitt Cancer Center, University of South Florida, Tampa, Florida, United States
  6. 6. Department of Oncology, Tabriz University of Medical Sciences, Tabriz, Iran
  7. 7. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  8. 8. Department of Medical Biochemistry, Faculty of Medicine, Ege University, Izmir, 35100, Turkey
  9. 9. Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
  10. 10. Department of Stem Cell, Institute of Health Sciences, Ege University, Izmir, 35100, Turkey

Source: Cancer Cell International Published:2022


Abstract

A pharmacological class known as immune checkpoint inhibitors (ICIs) has been developed as a potential treatment option for various malignancies, including HCC. In HCC, ICIs have demonstrated clinically significant advantages as monotherapy or combination therapy. ICIs that target programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1), as well as cytotoxic T lymphocyte antigen 4 (CTLA-4), have made significant advances in cancer treatment. In hepatocellular carcinoma (HCC), several ICIs are being tested in clinical trials, and the area is quickly developing. As immunotherapy-related adverse events (irAEs) linked with ICI therapy expands and gain worldwide access, up-to-date management guidelines become crucial to the safety profile of ICIs. This review aims to describe the evidence for ICIs in treating HCC, emphasizing the use of combination ICIs. © 2022, The Author(s).
Related Docs
View other Related Docs
1. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
2. Advanced Therapeutic Modalities in Hepatocellular Carcinoma: Novel Insights, Journal of Cellular and Molecular Medicine (2021)
3. Tumor Immunology, Clinical Immunology (2022)
4. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
5. Therapeutic and Immunomodulatory Potentials of Mesenchymal Stromal/Stem Cells and Immune Checkpoints Related Molecules, Biomarker Research (2024)
6. Advances in Therapeutic Targeting of Immune Checkpoints Receptors Within the Cd96-Tigit Axis: Clinical Implications and Future Perspectives, Expert Review of Clinical Immunology (2022)
7. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
8. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (17)
Hamid Reza Mirzaei (3)
Other Related Docs
9. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
10. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
11. Structure Based Screening for Inhibitory Therapeutics of Ctla-4 Unveiled New Insights About Biology of Acth, International Journal of Peptide Research and Therapeutics (2020)
12. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
13. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
14. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
15. The Prospect of Targeting T Cell Immunoglobulin and Mucin-Domain Containing-3 in Renal Cell Carcinoma Immunotherapy, Scandinavian Journal of Immunology (2022)
16. Nano-Immunotherapy: Overcoming Delivery Challenge of Immune Checkpoint Therapy, Journal of Nanobiotechnology (2023)
17. Biomarkers for Immune Checkpoint Inhibitors, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
18. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
19. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
20. Immune Checkpoints and Reproductive Immunology: Pioneers in the Future Therapy of Infertility Related Disorders?, International Immunopharmacology (2021)
21. Impact of Helicobacter Pylori Infection on the Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis, Immunotherapy (2023)
22. A Systematic Review and Meta-Analysis of Immune Checkpoint Therapy in Relapsed or Refractory Non-Hodgkin Lymphoma; a Friend or Foe?, Translational Oncology (2023)
23. Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer, Immunotherapy (2021)
24. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
25. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
26. Downregulation of Immunosuppressive Molecules, Pd-1 and Pd-L1 But Not Pd-L2, in the Patients With Multiple Sclerosis, Iranian Journal of Allergy# Asthma and Immunology (2016)
27. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
28. Immune Checkpoint Inhibitors and Cardiotoxicity: Possible Mechanisms, Manifestations, Diagnosis and Management, Expert Review of Anticancer Therapy (2021)
29. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms, Vaccines (2022)
30. How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer, International Immunopharmacology (2020)
31. Gene-Knocked Out Chimeric Antigen Receptor (Car) T Cells: Tuning up for the Next Generation Cancer Immunotherapy, Cancer Letters (2018)
32. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
33. The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities, Frontiers in Immunology (2021)
34. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)
35. Prolonged Persistence of Chimeric Antigen Receptor (Car) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward, Frontiers in Immunology (2020)
36. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
37. Immunotherapy in Nonmelanoma Skin Cancers, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
38. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)
39. Immunology of Cutaneous Tumors and Immunotherapy for Melanoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
40. Expression of Pd1 and Pdl1 As Immune-Checkpoint Inhibitors in Mantle Cell Lymphoma, BMC Cancer (2022)
41. Current Status of Transarterial Chemoembolization (Tace) Agents in Hepatocellular Carcinoma Treatment, Journal of Drug Delivery Science and Technology (2022)
42. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
43. Ctla-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer, Current Molecular Medicine (2023)
44. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
45. Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity, IUBMB Life (2021)
46. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
47. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
48. Melatonin and Cancer: From the Promotion of Genomic Stability to Use in Cancer Treatment, Journal of Cellular Physiology (2019)
49. Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy, Cancers (2022)
50. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)